HemaSphere (Aug 2023)
S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY
- Huilai Zhang,
- Jingwei Yu,
- He LI,
- Wenbin Qian,
- Xibin Xiao,
- Qingqing Cai,
- Yao Liu,
- Yu Zhang,
- Liling Zhang,
- Ling Qin,
- Hui Zhou,
- Xiaoyi Tang,
- Yingmei Guo,
- Hui Zhou,
- Ting Niu
Affiliations
- Huilai Zhang
- 1 Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
- Jingwei Yu
- 1 Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
- He LI
- 2 West China Hospital of Sichuan University, Chengdu, China
- Wenbin Qian
- 3 The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Xibin Xiao
- 3 The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Qingqing Cai
- 4 Sun Yat-sen University Cancer Center, Guangzhou, China
- Yao Liu
- 5 Chongqing University Cancer Hospital, Chongqing, China
- Yu Zhang
- 6 Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan, China
- Liling Zhang
- 6 Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan, China
- Ling Qin
- 7 The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
- Hui Zhou
- 8 Hunan Cancer Hospital, Changsha, China
- Xiaoyi Tang
- 10 Innovent Biologics Inc., Suzhou, China
- Yingmei Guo
- 10 Innovent Biologics Inc., Suzhou, China
- Hui Zhou
- 10 Innovent Biologics Inc., Suzhou, China
- Ting Niu
- 2 West China Hospital of Sichuan University, Chengdu, China
- DOI
- https://doi.org/10.1097/01.HS9.0000967776.81028.41
- Journal volume & issue
-
Vol. 7
p. e8102841
Abstract
No abstracts available.
